Premium
Concurrent cetuximab and postoperative radiation in resected high‐risk squamous cell carcinomas of the head and neck: A single‐institution experience
Author(s) -
Araki Daisuke,
Redman Mary W.,
Martins Renato,
Eaton Keith,
Baik Christina,
Chow Laura,
Goulart Bernardo,
Lee Sylvia,
Santana–Davila Rafael,
Liao Jay,
Parvathaneni Upendra,
Laramore George,
Futran Neal,
Mendez Eduardo,
Bhrany Amit,
Rodriguez Cristina P.
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24437
Subject(s) - cetuximab , medicine , oncology , hazard ratio , head and neck squamous cell carcinoma , radiation therapy , multivariate analysis , cisplatin , head and neck cancer , chemotherapy , cancer , confidence interval , colorectal cancer
Background Postoperative cisplatin and radiation is the standard of care for high‐risk squamous cell carcinoma of the head and neck (SCCHN). We have used cetuximab and radiation in the postoperative setting for patients deemed poor candidates for cisplatin. Methods We retrospectively identified 40 patients who received cetuximab and radiation for resected locoregionally advanced SCCHN between 2006 and 2013 at our institution. Results The 2‐year Kaplan–Meier estimates were: overall survival (OS) 41%, recurrence‐free survival (RFS) 34%, locoregional control 63%, and distant metastatic control 59%. Eastern Cooperative Oncology Group (ECOG) performance status ≥1 predicted for inferior OS (hazard ratio [HR] = 5.43; p = .003), RFS (HR = 4.07; p = .007), and locoregional control (HR = 4.92; p = .04) in multivariate analysis. Conclusion Patients with resected high‐risk SCCHN treated with postoperative cetuximab and radiation have suboptimal therapeutic outcomes. Further study of the efficacy and cost‐effectiveness compared to radiation alone is warranted. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1318–1323, 2016